MODIFIED PTO/SB/08a (05-07) Approved for use through 11/30/2007.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/588,485
Confirmation Number	8206
Filing Date	August 4, 2006
First Named Inventor	Masaaki HIRANO
Art Unit	1626
Examiner Name	Valerie Rodriguez-Garcia
Attorney Docket Num	ber Q96434

	U.S. PATENTS						
Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1						

	U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initials*	I CITE NO I PUNICATION NUMBER		Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1	2005/0267110	A1	2005-12-01	M. Hirano		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	1	2000-95767	JP		2000-04-04	Y. Imaeda et al.		Abstract
	2	1 300 398	EP	A1	2003-04-09	Masaaki Hirano et al.		
	3	2005/118556	wo	A1	2005-12-15	Masaaki Hirano et al.		Abstract
	4	1 752 452	EP	A1	2007-02-14	Masaaki Hirano et al.		
	5	02/102401	wo	A1	2002-12-27	Jorgen Engel et al.		
	6	2005/030736	wo	A1	2005-04-07	Giovanni Meazza et al.		
	7	01-249792	JP	Α	1989-10-05	K. Kato et al.		Abstract

	NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	L CITE NO. I (book magazine journal serial symposium catalog etc.) date page(s) volumeussue number(s) publisher il				
	1	CHARLES HUGGINS ET AL., "Studies on Prostatic Cancer", Cancer Research, 1, 293-297 (1941).			
	2	L. BOKSER ET AL., "Prolonged Inhibition of Luteinizing Hormone and Testosterone Levels in Male Rats with the Luteinizing Hormone-Releasing Hormone Antagonist SB-75", Proc. Natl. Acad. Sci. USA, 87, pp. 7100-7104, Sept. 1990.			
	3	ANA MARIA COMARU-SCHALLY ET AL., "Efficacy and Safety of Luteinizing Hormone-Releasing Hormone Antagonist Cetrorelix in the Treatment of Symptomatic Benign Prostatis Hyperplasia," Journal of Clinical Endocrinology and Metabolism, Vol. 83, No. 11, pp. 3826-3831 (1998).			
	4	I.B. DZVINCHUK ET AL., "Formation of Unsymmetrical 2-(Diacylmethylene)-2,3-Dihydro-1 H-Benzimidazoles During Acidolysis of 1-Benzoyl-2-((3-Benzoyloxy-(3-Phenylvinyl)-1 H-Benzimidazole), Chemistry of Heterocyclic Compounds, 37(5), 554-559 (2001).			
	5	SEMA OZTURK ET AL., "Crystal Structure of 2-Dibenzoylmethyl Benzimidazole", Analytical Sciences, Vol. 17,pp. 1133-1134, (2001).			
	6	MANFRED AUGUSTIN ET AL, "Synthesis and reactions of 2,2-diacylketene heteroacetals", Zeitschrift fuer Chemie(1980), 20(3), 96-7.			
	7	JUNKO ISHIDA et al., "Antitumor Agents. Part 214: Synthesis and Evaluation of Curcumin Analogues as Cytotoxic Agents," Bioorganic & Medicinal Chemistry 10 (2002) 3481-3487.			
	8	Science of Synthesis, "Product Subclass 17: 1,1-Bis(nitrogen - functionalized) Alk - 1-enes", 24, 571-705 (2005).			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3).

3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /V.R.G

EXAMINER SIGNATURE							
Examiner Signature	/Valerie Rodriguez-garcia/	Date Considered	07/09/2009				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3).

3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /V.R.G